Online Only Articles

Hyper-CVAD + epratuzumab as a salvage regimen for younger patients with relapsed/refractory CD22-positive precursor B-cell acute lymphocytic leukemia

Hematology Department, CHU Hotel-Dieu, Nantes, France
Hematology Department, CHU, Caen, France
Hematology Department, CHU, Toulouse, France
Hematology Department, Hôpital Saint-Louis, Paris, France
Hematology Department, CHU, Lyon, France
Hematology Department, CHU, Bordeaux, France
Hematology Department, CHU, Rennes, France
Hematology Department, Hopital Saint-Antoine, Paris, France
Hematology Department, Institut Paoli-Calmette, Marseille, France
Hematology Department, CHU Henri Mondor, Créteil, France
Hematology Department, CHU, Poitiers, France
Hematology/Biology, CHU Hotel-Dieu, Nantes, France
Hematology Department, CHU Hotel-Dieu, Nantes, France
Hematology Department, CHU Hotel-Dieu, Nantes, France
Hematology Department, CHU Hotel-Dieu, Nantes, France
Hematology Department, CHU Hotel-Dieu, Nantes, France
Hematology Department, CHU Hotel-Dieu, Nantes, France
Immunomedics, Inc., Morris Plains, NJ, USA
Immunomedics, Inc., Morris Plains, NJ, USA
Hematology/Biology, CHU Hotel-Dieu, Nantes, France
Hematology Department, Hôpital Saint-Louis, Paris, France
Vol. 102 No. 5 (2017): May, 2017 https://doi.org/10.3324/haematol.2016.159905